Edition:
United Kingdom

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

23.00USD
19 Jan 2018
Change (% chg)

$-0.65 (-2.75%)
Prev Close
$23.65
Open
$23.90
Day's High
$24.65
Day's Low
$22.95
Volume
81,607
Avg. Vol
141,855
52-wk High
$30.35
52-wk Low
$14.95

Chart for

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.73
Market Cap(Mil.): $784.83
Shares Outstanding(Mil.): 37.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Lannett Names Timothy Crew To Board Of Directors

* LANNETT COMPANY INC - ‍ WITH CREW'S APPOINTMENT, TOTAL NUMBER OF DIRECTORS IS SEVEN​ Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Lannett Appoints Timothy Crew As CEO

* LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY

21 Dec 2017

BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution

* LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT

01 Dec 2017

BRIEF-Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL

* LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®

29 Nov 2017

BRIEF-Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

* Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

06 Nov 2017

BRIEF-Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing‍​

* Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing‍​ Source text : ( http://bit.ly/2zi8xIn ) Further company coverage:

06 Nov 2017

BRIEF-Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"

* Lannett Company Inc - ‍comments on amended civil generic drug price-fixing complaint ​

01 Nov 2017

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

30 Oct 2017

BRIEF-Lannett receives two FDA approvals for Lansoprazole, one each for full prescription and OTC

* Lannett receives two fda approvals for Lansoprazole delayed-release capsules usp, one each for full prescription and OTC

02 Oct 2017

BRIEF-Lannett receives FDA approval for Oxycodone and Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg

* Lannett receives FDA approval for Oxycodone And Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg

27 Sep 2017

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $104.64 +0.83
Pfizer Limited (PFIZ.NS) Rs2,123.00 +22.70
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,490.35 +28.85

Earnings vs. Estimates